Ejung Moon is a Group Leader in Radiation Biology and the Tumour Microenvironment at the Department of Oncology, University of Oxford's Medical Sciences Division. Her research focuses on hypoxia-driven tumor progression and radiation response mechanisms. Education: PhD in Pharmacology and Cancer Biology from Duke University Training: Postdoctoral work with Amato Giaccia at Stanford University Research Interests: Elucidating how hypoxia-induced MAFF protein regulates tumor cell invasion, metastasis, and radiation resistance through antioxidant response pathways. Current work explores MAFF dimerization dynamics and metabolic reprogramming in hypoxic tumors. Scientific Contributions: Identified MAFF's role in radiation-induced antioxidant gene regulation (2021, Nature Communications ). Recent studies investigate iron metabolism's impact on FLASH radiotherapy effects. Scientific Awards: Breast Cancer Research Program (BCRP) predoctoral fellowship Laboratory & Collaborations: Moon Lab collaborates with Oxford Cancer and NHS Cancer and Haematology Centre. Key partnerships include Stanford University's radiobiology research groups.
Pascal Frossard is a Full Professor at the Department of Electrical Engineering in the School of Engineering (STI) at EPFL, with a courtesy appointment in the School of Computer and Communication Sciences. He founded and directs the LTS4 laboratory since 2003, co-leads the EPFL AI Center and Swiss Data Science Center, and serves as Associate Dean for Research at STI. Research Focus: Machine Learning, Graph Signal Processing, AI Applications in Healthcare, Computer Vision Academic Leadership: IEEE Fellow, ELLIS Fellow, Conference Chair roles Key Projects: Digital Pathology for Oncology, Cardiac Digital Twins, Robust Machine Learning Research Interests: His work bridges signal processing, machine learning, and applied mathematics, emphasizing biomedical applications. Recent research includes adversarial robustness in classifiers, network representation learning, and 360-degree video analysis. Scientific Awards: IEEE Fellow ELLIS Fellow Leadership in IEEE technical committees Advising & Grants: Supervised 20+ PhD students and postdocs. Secured major grants from PHRT, Hasler Foundation, FNS-Sinergia, Armasuisse, Google, and Cisco.
Harris H. Wang is an Associate Professor in the Department of Systems Biology and Department of Pathology and Cell Biology at Columbia University's Vagelos College of Physicians and Surgeons, where he also serves as Interim Chair of Systems Biology. He is affiliated with the Center for Computational Biology and Bioinformatics (C2B2) and the Integrated Program in Cellular, Molecular and Biomedical Studies (CMBS). B.S., Physics and Mathematics, MIT Ph.D., Biophysics, Harvard University Dr. Wang's research lies at the intersection of systems and synthetic biology, focusing on developing foundational technologies for genome engineering, microbiome manipulation, and synthetic genomics. His lab pioneers methods such as MAGE, MAGIC, CAST, and CAMII to enable high-throughput genetic manipulation, in situ microbiome engineering, and AI-driven microbial culturomics. Key research themes include understanding microbial community dynamics, engineering cellular memory systems, designing biocontained genetic circuits, and applying synthetic biology to human health challenges in personalized medicine and infectious disease. His recent publications reveal a strong trend in spatial and functional metagenomics, CRISPR-based microbiome editing, and synthetic biology tools for data storage and genetic stability. The articles span high-impact journals like Nature , Science , and Nature Biotechnology , reflecting his leadership in developing scalable, programmable biological systems. Scientific Awards: NIH Director’s Early Independence Award Forbes 30 Under 30 in Science Sloan Research Fellowship NSF CAREER Award ONR Young Investigator Award Burroughs Wellcome Fund PATH Award Schaefer Scholar Blavatnik National Award Vilcek Prize PECASE Dr. Wang has advised numerous PhD and postdoctoral researchers, many of whom have gone on to independent scientific careers. His lab is supported by major grants from NIH, NSF, DARPA, DOE, and foundations including the Bill & Melinda Gates Foundation and CZ Biohub NY. He is actively involved in educational initiatives, including organizing Columbia’s iGEM team and the Cold Spring Harbor Laboratory Synthetic Biology course. The Wang Lab is based at the Columbia University Irving Medical Center and is part of national consortia such as the Engineering Biology Research Consortium (EBRC) and the Genome Project-Write (GP-Write) initiative. The lab develops and applies cutting-edge technologies in automation, machine learning, and synthetic biology to engineer microbiomes for applications in medicine, global health, and climate change.
Dr. Jimeng Sun is a Health Innovation Professor at the Siebel School of Computing and Data Science and Carle Illinois College of Medicine at the University of Illinois Urbana-Champaign. Co-founder of Keiji AI , he leads groundbreaking research at the intersection of artificial intelligence and healthcare, actively deploying clinical AI systems and developing frameworks like PyHealth and Therapeutics Data Commons . His research spans four major areas: Clinical AI Systems : Developing interpretable models (e.g., RETAIN) for patient similarity, temporal event prediction, medication recommendation, and clinical outcome forecasting Drug Discovery : Creating molecular optimization frameworks, drug-target interaction models, and AI-driven platforms Clinical Trials : Pioneering patient-trial matching, outcome prediction, and optimization frameworks using deep learning and graph neural networks Biosignal Analysis : Advancing sleep staging, seizure classification, and automated EEG/Cardiac monitoring systems With over 500 top-tier publications (including in Nature , NEJM AI , and leading AI conferences) and an h-index of 99, his work has been recognized with the Top 100 AI Leaders in Drug Discovery and Advanced Healthcare award. He maintains active collaborations with institutions like Massachusetts General Hospital , Medidata Solutions , and OSF Healthcare . His recent publications reveal a strong focus on: Reinforcement learning applications in medical data analysis Large language model adaptation for clinical tasks Knowledge graph integration with AI systems Synthetic data generation for healthcare Multi-modal learning in clinical contexts Explainable AI for medical applications Dr. Sun's lab ( Sunlab ) emphasizes practical impact over theoretical work, actively collaborating with hospitals and healthtech companies. He welcomes contributions from clinicians, researchers, and industry partners through initiatives like his AI for Health webinar series .
Sriram Subramaniam is a Professor in the Department of Biochemistry and Molecular Biology at the University of British Columbia (UBC) and holds the Gobind Khorana Canada Excellence Research Chair in Precision Cancer Drug Design. His research leverages cryo-electron microscopy (cryo-EM) to advance structural biology and drug design, focusing on protein dynamics and therapeutic target identification. Education: PhD in Physical Chemistry (1987) from Stanford University; MSc in Chemistry (1981) from Indian Institute of Technology, Kanpur. Subramaniam's interdisciplinary work combines cryo-EM with computational tools and molecular biology to study protein structures at atomic resolution. His lab has pioneered cryo-EM applications in precision medicine, including mapping small molecule drugs on patient-specific cancer mutants. Recent publications (2024-2022) highlight his contributions to understanding SARS-CoV-2 immune evasion, structural mechanisms of ATPases, and AI integration in structural biology. His research spans viral entry mechanisms, CRISPR systems, and neurodegenerative disease pathways. Scientific Awards: Gobind Khorana Canada Excellence Research Chair NIH Director’s Award for Scientific Excellence Fellow of the Biophysical Society Breakthrough Prize nomination Based at the Djavad Mowafaghian Center for Brain Health, Subramaniam leads the Program in Cryo-EM Guided Drug Design, contributing to over 177 peer-reviewed publications with a career h-index of 58 and citations exceeding 12,340.
Daniel Finley is a Professor of Cell Biology at Harvard Medical School (HMS), leading the Finley Lab focused on the ubiquitin-proteasome pathway and related regulatory mechanisms. He holds academic appointments within the Department of Cell Biology and sits on the Scientific Advisory Boards of Proteostasis and X-Chem Pharmaceuticals. His research investigates proteasome function, ubiquitin-like proteins, and proteostasis roles in diseases like Alzheimer’s and ALS. Dr. Finley earned his undergraduate degree in biochemistry from Harvard University and a Ph.D. in molecular biology from MIT. After postdoctoral training at MIT, he joined HMS in 1988. His lab explores topics including erythroid proteome remodeling, mitochondrial dysfunction, and neurodegenerative disease mechanisms. Key research areas include: (1) Ubiquitin-proteasome pathway regulation, (2) Proteasome structure/function, (3) Nonproteolytic roles of ubiquitination, and (4) Pathophysiological roles of proteostasis defects in diseases. His work bridges basic cell biology with translational medicine, particularly in neurodegeneration and anemia. Finley has secured NIH funding for projects like 'Regulation of Proteasome Activity' (R35GM145246) and 'Erythrocyte maturation through global proteome remodeling' (R01HL153970). Collaborations with industry and academic partners extend his impact in drug discovery and proteasome-targeted therapies. His lab’s contributions include defining ubiquitin chain editing mechanisms, identifying USP14’s role in mitophagy, and elucidating proteostasis defects in Alzheimer's models. Research tools developed include advanced cryo-EM analyses of proteasomal structures and functional assays for ubiquitin system enzymes.
Julienne Bower is a Professor at the University of California, Los Angeles (UCLA) with joint appointments in the Department of Psychology and the Department of Psychiatry/Biobehavioral Sciences. She serves as Director of the Mind-Body Research Lab, Associate Director of the Cousins Center for Psychoneuroimmunology, and as a Member of the Jonsson Comprehensive Cancer Center. Her research explores mind-body interactions in individuals facing stressful life events, particularly cancer patients and survivors, focusing on biological pathways linking psychological states to health outcomes and the effects of mind-body interventions. Ph.D. from UCLA Area Chair: Health Psychology Primary Area: Health Psychology Secondary Area: Clinical Psychology Location: 6538 Pritzker Hall, UCLA Dr. Bower's research examines how positive psychological factors (e.g., benefit finding, positive affect) influence physical health through immune and neuroendocrine pathways, while also investigating mind-body interventions like yoga and mindfulness meditation. Her work spans observational, experimental, and intervention studies, emphasizing the immune system as a central mechanism. The Mind-Body Research Lab, under Dr. Bower's leadership, has published extensively on topics including cancer-related fatigue, stress-induced inflammation, and the physiological impacts of psychosocial interventions. Key publications address NF-κB signaling, glucocorticoid resistance, and cortisol dysregulation in cancer survivors. Dr. Bower's lab is actively recruiting graduate students for 2024 through the UCLA Health Psychology Program, offering training in psychoneuroimmunology, cancer prevention, and mind-body research methodologies.
Associate Professor Adam Irwin is an NHMRC Emerging Leadership Fellow and Associate Professor in Infectious Diseases at the University of Queensland (UQ) and Queensland Children’s Hospital. He holds positions within the UQ Centre for Clinical Research, Faculty of Health, Medicine and Behavioural Sciences. His work focuses on early sepsis recognition, antimicrobial stewardship, and pediatric infectious diseases. Dr. Irwin completed his medical degree at the University of Birmingham and his PhD in 2016 from the University of Liverpool’s Institute of Infection and Global Health. He has led initiatives like the Queensland Paediatric Sepsis Program, recognized with a Global Sepsis Alliance Award and Queensland Health Excellence Awards. His research spans sepsis pathway implementation, antimicrobial resistance trends, and rapid diagnostic tools. Notable grants include NHMRC funding for studies on multi-drug resistant infections and Children’s Hospital Foundation support for genomics and antimicrobial stewardship projects. He supervises PhD candidates in areas like bloodstream infections and molecular diagnostics. Dr. Irwin collaborates across institutions, contributing to projects such as the RAPIDS Study Group and the PAEDS surveillance network. Awards include the NHMRC Emerging Leadership Fellowship and recognition for sepsis program excellence. His work emphasizes translating research into clinical practice, improving outcomes for critically ill children through evidence-based protocols and innovative diagnostics.
Pierre Vandergheynst is a Full Professor at the Swiss Federal Institute of Technology Lausanne (EPFL) in the Department of Electrical Engineering, with a courtesy appointment in Computer and Communication Sciences. He serves as EPFL’s Vice-Provost for Education since 2015 and leads the Signal Processing Laboratory 2 (LTS2). His research spans harmonic analysis, sparse approximations, mathematical data processing, and applications in signal/image processing, computer vision, machine learning, and graph-based data analysis. PhD in Mathematical Physics (1998), Université catholique de Louvain Postdoctoral Researcher at EPFL (1998-2001) Assistant Professor at EPFL (2002-2007) His research explores geometry/symmetry in high-dimensional data, redundant dictionaries for dimensionality reduction, and computational harmonic analysis on manifolds. Recent work focuses on protein structure modeling, geometric deep learning, and graph-based signal processing. Key article trends include graph neural networks for protein analysis, geometric deep learning in neuroscience, and structured knowledge priors in neural models. His 2023-2025 publications emphasize interpretable AI, long-range dependencies in graphs, and molecular representation learning. Scientific Awards: IEEE Signal Processing Magazine Best Paper Award (2023) Signal Processing Society Best Paper Award (2022) Apple ARTS Award (2007) De Boelpaepe Prize, Royal Academy of Sciences of Belgium (2009-2010) He has supervised over 30 PhD theses and contributed to foundational work in graph signal processing, compressive sensing, and geometric deep learning. His lab develops tools for data science on non-Euclidean structures, with applications in medicine, astronomy, and wireless systems.
James B. Kaper is a Professor and Chair of the Department of Microbiology & Immunology at the University of Maryland School of Medicine. He serves as Vice Dean for Academic Affairs and previously held leadership roles as Senior Associate Dean (2014–2019) and Chair (2007–present). His research focuses on the molecular pathogenesis of diarrheagenic Escherichia coli and Vibrio cholerae , including vaccine development and bacterial-host interactions. Education: BS (1973) and PhD (1979) in Microbiology from University of Maryland; Postdoc in Molecular Pathogenesis at University of Washington (1979–1981) Dr. Kaper’s work has led to the creation of live attenuated cholera vaccines, including CVD 103-HgR, the first licensed recombinant bacterial vaccine. His lab investigates bacterial genetics, intestinal colonization, and immune system activation, particularly TLR5 response to V. cholerae flagellin. He has authored 303 peer-reviewed articles and 68 book chapters. His research has been funded continuously by NIAID since 1982. Key publications include foundational work on V. cholerae vaccines (1984), genomic structure (1998), and quorum sensing in EHEC/EPEC (1999). His lab’s recent studies focus on phosphotyrosine proteomics (2013) and pathogenicity island regulation (2007). Scientific awards: Fellow, American Academy of Microbiology (1994); NIH Merit Award (2004); ASM DC White Award (2019) Editorial roles: Editor-in-Chief, EcoSal (2006–present); Associate Editor, International Journal of Medical Microbiology (2000–present) As an academic leader, Dr. Kaper has mentored over 60 graduate students and postdoctoral fellows. He holds multiple patents for cholera vaccines and E. coli diagnostics, including U.S. Patents 4,935,364; 5,399,494; and 6,204,004. His lab at UMSOM combines basic science with translational applications for enteric disease prevention.
Ning Zhang is an Assistant Professor in the Biology Department at James Madison University (JMU), joining in 2024. Her research focuses on enhancing crop resilience through molecular and biochemical studies of plant defense mechanisms against bacterial pathogens, alongside developing genome editing technologies for trait improvement. She holds a PhD in Horticulture and Crop Science from The Ohio State University (2016), an MS in Silviculture from Zhejiang Agriculture and Forestry University (2011), and a BS in Landscape Architecture from Shandong Agricultural University (2008). Research Interests: Dr. Zhang's lab investigates plant immunity pathways, CRISPR/Cas9 genome editing applications, and engineering crops for disease resistance. Her work integrates molecular biology, genetics, and biochemistry to tackle challenges posed by climate change and biotic/abiotic stresses. Recent Trends in Publications: Her articles concentrate on MAPK signaling pathways, NLR protein interactions, PP2C phosphatase regulation, and bacterial effector mechanisms in tomato and other crops. Key themes include immune system activation, pathogen recognition diversity, and transgenic plant development. Lab Information: The Zhang Lab at JMU is part of the Department of Biology, focusing on plant biotechnology solutions for agricultural sustainability. They collaborate on projects involving CRISPR-based gene editing and stress tolerance research.
Dr. Samira Lakhal-Littleton is an Associate Professor of Cell Physiology and MRC Senior Non-Clinical Research Fellow at the University of Oxford, affiliated with the Department of Physiology, Anatomy and Genetics and Brasenose College. Her research focuses on iron homeostasis, systems biology, and oxygen sensing mechanisms in cardiovascular and systemic physiology. Education: BSc in Human Genetics (University College London), DPhil in Molecular Medicine (University of Oxford) Her work bridges cell physiology and translational medicine, with key discoveries on hypoxia-inducible factors (HIFs), iron regulatory genes TMPRSS6 and GDF15 , and the role of hepcidin in altitude adaptation and chronic diseases. She utilizes tissue-specific animal models to study iron regulation in heart, kidney, placenta, and vasculature. Recent publications highlight her contributions to understanding: FLASH radiotherapy effects linked to iron-dependent lipid peroxidation Clinical implications of myocardial iron dynamics in heart failure Hepcidin's role in vascular protection and placental iron transfer Biomarker development for predictive iron deficiency diagnostics Scientific Leadership: British Heart Foundation Intermediate Fellowship (2012) MRC Senior Fellowship (2020) BioIron Society Board Member (2019) She collaborates with clinical teams on translational projects and serves as a Tutorial Fellow in Medicine at Brasenose College, mentoring students in physiological sciences.
Karen Piper Hanley is Professor of Molecular Medicine and Head of Division in the Division of Diabetes, Endocrinology & Gastroenterology at the University of Manchester. She serves as the fibrosis lead in the Wellcome Trust Centre for Cell-Matrix Research and previously served as Director of Core Research Technologies (2019-2022). She is also an editorial board member for Scientific Reports. Her research focuses on fibrosis (scarring) mechanisms across multiple organs, particularly liver, kidney, and lung fibrosis. Her lab investigates the cellular and molecular basis of fibrotic disease, with emphasis on how pathological scar components are produced and how they signal to surrounding cells. Key areas include the role of SOX9 transcription factor, integrin beta-1 signaling, Group 1 PAKs, and YAP1 in fibrosis progression. Her recent publications reveal trends toward increased clinical translation of fibrosis research, with studies on health inequalities in liver cancer care, post-COVID diabetes incidence, and innovative approaches to liver disease detection. Her work increasingly integrates spatial transcriptomics and advanced omics technologies to understand cellular transitions in liver disease. Career-track postdoctoral fellowship from the University of Southampton (2006) As senior postgraduate tutor, she has mentored numerous PhD students who have presented at key conferences and authored high-quality manuscripts. All her PhD students have submitted and been awarded their degrees within 4 years. She has successfully guided previous Academic Clinical Fellows to win MRC clinical training fellowships. Her teaching extends to undergraduate Personal & Professional Development and supervision of MRes and BSc students, many of whom have achieved first-class degrees and prestigious awards. Her lab maintains active collaborations with Professor Neil Hanley's group on human development, stem cells, and regenerative medicine, bridging developmental biology with fibrosis research to understand why regeneration is impaired in chronic diseases.
Dr. Giulia Biancon is an Assistant Professor Adjunct in the Department of Medical Oncology and Hematology at Yale School of Medicine. She holds a PhD from the University of Milan (2019) and is a member of the Halene Lab, focusing on RNA biology and hematologic malignancies. Her research combines high-throughput methodologies to study RNA mechanisms in diseases like myeloid leukemias and splicing factor mutations. Education: PhD in Molecular Biology from the University of Milan (2019). Research Interests: RNA splicing, stress granules in cancer, epitranscriptomics, clonal hematopoiesis, and the interplay between genetic mutations and cellular pathways in blood cancers. Awards: 2024 Eclipse Award, 2022 ASH Abstract Achievement Award, and 2022 RNA Society Best Poster Award. Her work has been published in journals like Cell Reports , Blood , and Molecular Cell . Labs/Teams: Principal member of the Halene Lab and coordinator at the Yale Center for RNA Science and Medicine. Collaborates with institutions like the SeroNet network for immunology studies.
Peter Brodersen is a Professor at the Department of Biology, University of Copenhagen , specializing in Bioinformatics and RNA Biology . His research focuses on RNA modification (m6A), YTHDF proteins, and small RNA pathways in plants. Recent research trends from his group include: (1) molecular mechanisms of ARGONAUTE-small RNA interactions, (2) m6A-YTHDF regulatory systems in plant development, and (3) RNAi-independent roles of DICER-LIKE proteins in antiviral defense. Collaborations span Denmark and international institutions. Publications highlight cross-disciplinary work bridging computational biology and experimental plant genetics. Key subfields include RNA structure, epigenetic regulation, and antiviral immunity.
